BDSX vs. XGN, EUDA, SERA, QIPT, NAKA, KDLY, ATPC, CORBF, OPGN, and PIII
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), Global Cord Blood (CORBF), OpGen (OPGN), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.
Biodesix vs. Its Competitors
Biodesix (NASDAQ:BDSX) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Biodesix has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
21.0% of Biodesix shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 30.1% of Biodesix shares are owned by insiders. Comparatively, 12.6% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Exagen has a net margin of -27.34% compared to Biodesix's net margin of -54.28%. Exagen's return on equity of -133.69% beat Biodesix's return on equity.
Biodesix currently has a consensus price target of $1.75, indicating a potential upside of 468.18%. Exagen has a consensus price target of $7.50, indicating a potential upside of 7.60%. Given Biodesix's higher probable upside, research analysts clearly believe Biodesix is more favorable than Exagen.
In the previous week, Biodesix's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.
Exagen has lower revenue, but higher earnings than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
Summary
Exagen beats Biodesix on 9 of the 14 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 7/10/2025 by MarketBeat.com Staff
Free BDSX Stock Alerts